文献速递白血病造血干细胞移植与细胞治疗

靶向cyclin A1特异性T细胞治疗急性髓系白血病的可行性评估

Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

本研究探索靶向癌睾丸抗原cyclin A1(CCNA1)的T细胞作为急性髓系白血病(AML)治疗策略的潜力。CCNA1在恶性原始细胞和白血病干细胞中过表达,对天然T细胞具有免疫原性,超过90%的供者筛查可产生特异性反应。扩增的T细胞为Th1极化、多功能且对CCNA1+/HLA匹配的肿瘤细胞系有细胞毒性,且对CCNA1高度特异,不与包括CCNA2在内的其他cyclin家族成员反应。HSCT后AML患者中检测到CCNA1特异性T细胞与疾病缓解延长相关。

要点

  • CCNA1在AML原始细胞和白血病干细胞中过表达,对天然T细胞具免疫原性
  • 超过90%供者筛查可产生CCNA1特异性T细胞反应
  • 扩增T细胞为Th1极化、多功能、对CCNA1+/HLA匹配肿瘤细胞系有细胞毒性且高度特异

核心结论

  • 靶向CCNA1具有可行性,过继转移反应性T细胞可能带来治疗获益。
  • HSCT后内源性CCNA1特异性T细胞与AML疾病缓解延长相关,提示其保护潜力。

研究设计与样本

  • 本研究探索靶向cyclin A1(CCNA1)的T细胞作为AML治疗策略的潜力。
  • 研究评估了CCNA1对天然T细胞的免疫原性,并检测了扩增T细胞的表型和杀伤功能。

主要发现

  • 超过90%的供者筛查可产生针对CCNA1的特异性T细胞反应。
  • 扩增的T细胞为Th1极化、多功能,且对CCNA1+/HLA匹配的肿瘤细胞系有细胞毒性。
  • 这些T细胞对CCNA1高度特异,不与包括CCNA2在内的其他cyclin家族成员反应;CCNA2与CCNA1有56%同源性且在分裂细胞中普遍表达。
  • HSCT后AML患者中检测到CCNA1特异性T细胞与疾病缓解延长相关。

关键数值与推荐

  • 超过90%的供者筛查可产生针对CCNA1的特异性T细胞反应。
  • CCNA2与CCNA1有56%同源性,且在分裂细胞中普遍表达。

临床怎么用

  • CCNA1特异性T细胞过继转移可能作为AML(尤其HSCT后复发)的潜在治疗策略。
  • HSCT后监测CCNA1特异性T细胞或有助于评估疾病缓解状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option for relapsed or refractory acute myeloid leukemia (AML). However, more than half ultimately experience disease relapse that is associated with a dismal median survival of just 6 months, highlighting the need for novel therapies. In the current study we explore the therapeutic potential of targeting cyclin A1 (CCNA1), a cancer-testis antigen that is overexpressed in malignant blasts and leukemic stem cells. We demonstrate the immunogenicity of this antigen to native T cells, with >90% of donors screened mounting a specific response. The expanded cells were Th1 polarized, polyfunctional, and cytotoxic toward CCNA1+/HLA-matched tumor cell lines. Furthermore, these cells were exquisitely specific for CCNA1 and exhibited no reactivity against other cyclin family members, including CCNA2, which shares 56% homology with CCNA1 and is ubiquitously expressed in dividing cells. Lastly, the detection of CCNA1-specific T cells in AML patients post-HSCT was associated with prolonged disease remission, suggesting the protective potential of such endogenous cells. Taken together, our findings demonstrate the feasibility of targeting CCNA1 and the potential for therapeutic benefit associated with the adoptive transfer of reactive cells.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Leung WK, Workineh A, Mukhi S, et al. Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020. PMID: 31985805. doi:10.1182/bloodadvances.2019000715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。